Molecular Basis of Lys-63-linked Polyubiquitination Inhibition by the Interaction between Human Deubiquitinating Enzyme OTUB1 and Ubiquitin-conjugating Enzyme UBC13

Received for publication, March 20, 2012, and in revised form, May 16, 2012 Published, JBC Papers in Press, June 7, 2012, DOI 10.1074/jbc.M112.364752

Yusuke Sato‡, Atsushi Yamagata†§, Sakurako Goto-Ito†, Keiko Kubota‡, Rikako Miyamoto‡, Shinichiro Nakada†¶, and Shuya Fukai†§‡

From the ‡Structural Biology Laboratory, Life Science Division, Synchrotron Radiation Research Organization and Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo 113-0032, Japan, the §Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Chiba 277-8501, Japan, the ¶Center of Integrated Medical Research, School of Medicine, Keio University, Tokyo 160-8582, Japan, and the †Department of Bioregulation and Cellular Response, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan

Background: A deubiquitinating enzyme OTUB1 inhibits Lys-63-linked ubiquitination by binding to a ubiquitin-conjugating enzyme UBC13.

Results: A mechanism of human OTUB1-UBC13 interaction was revealed by human OTUB1-UBC13-MMS2 complex structure and structure-based mutagenesis.

Conclusion: The atomic-level interactions presented by the OTUB1-UBC13-MMS2 complex structure are critical for Lys-63-linked ubiquitination inhibition.

Significance: Learning how ubiquitination is regulated by the OTUB1-UBC13 interaction is crucial for understanding DNA damage response in biology.

UBC13 is the only known E2 ubiquitin (Ub)-conjugating enzyme that produces Lys-63-linked Ub chain with its cofactor E2 variant UEV1a or MMS2. Lys-63-linked ubiquitination is crucial for recruitment of DNA repair and damage response molecules to sites of DNA double-strand breaks (DSBs). A deubiquitinating enzyme OTUB1 suppresses Lys-63-linked ubiquitination of chromatin surrounding DSBs by binding UBC13 to inhibit its E2 activity independently of the isopeptidase activity. OTUB1 strongly suppresses UBC13-dependent Lys-63-linked tri-Ub production, whereas it allows di-Ub production in vitro. The mechanism of this non-canonical OTUB1-UBC13-mediated inhibition of ubiquitination remains to be elucidated. Furthermore, the atomic level information of the interaction between human OTUB1 and UBC13 has not been reported. Here, we determined the crystal structure of human OTUB1 in complex with human UBC13 and MMS2 at 3.15 Å resolution. The presented atomic-level interactions were confirmed by surface-plasmon resonance spectroscopy with structure-based mutagenesis. The designed OTUB1 mutants cannot inhibit Lys-63-linked Ub chain formation in vitro and histone ubiquitination and 53BP1 assembly around DSB sites in vivo. Finally, we propose a model for how capping of di-Ub by the OTUB1-UBC13-MMS2/UEV1a complex efficiently inhibits Lys-63-linked tri-Ub formation.

Ubiquitin (Ub)³ is a highly conserved 76-residue protein that can be covalently attached to substrate proteins to control a wide variety of biological processes (1, 2). The enzymatic cascade of ubiquitination includes three distinct classes of enzymes: (i) a Ub-activating enzyme E1 for attaching Ub to the active site Cys via a thioester bond in an ATP-dependent manner; (ii) a Ub-conjugating enzyme E2 for receiving Ub from E1 to the active site Cys; (iii) a Ub ligase E3 for aiding transfer of Ub from E2 to specific lysine residues of substrate proteins. E3s are classified into two groups; the HECT domain-containing E3s have a catalytic Cys and transfer Ub from E2 to substrates via Ub-charged E3 intermediates (E3~Ub), whereas the RING domain-containing E3s bridge E2 and substrates to enable the Ub transfer between them. E1, E2, and E3 enzymes work together to conjugate the terminal carboxyl group of Ub with the ε-amino group of lysine residues of substrate proteins including Ub itself. Ub has seven lysine residues and one terminal amino group, all of which can be attached to additional Ub.

* This work was supported by KAKENHI from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan (to S. F., Y. S., and S. N.), the Promotion of Environmental Improvement for Independence of Young Researchers “Kanrinmaru Project” from MEXT (to S. N.), and grants from Takeda Science Foundation (to S. N.), Kato Memorial Bioscience Foundation (to S. N.), and The Nakajima Foundation (to S. F.).

† This article contains supplemental S1–S6. The atomic coordinates and structure factors (code3VON) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

‡ To whom correspondence may be addressed: Dept. of Bioregulation and Cellular Response, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan. Tel.: 81-6-6879-3398; E-mail: snakada/res@gmail.com.

§ To whom correspondence may be addressed: Structural Biology Laboratory, Life Science Division, Synchrotron Radiation Research Organization and Institute of Molecular and Cellular Biosciences, the University of Tokyo, Tokyo 113-0032, Japan. Tel.: 81-3-5841-7807; E-mail: fukai@iam.u-tokyo.ac.jp.

¶ To whom correspondence may be addressed: School of Medicine, Osaka University, Osaka 565-0871, Japan.

© 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
Crystal Structure of Human OTUB1-UBC13-MMS2 complex

EXPERIMENTAL PROCEDURES

Preparation of the OTUB1-ΔN-UBC13-MMS2 Complex—The genes encoding human OTUB1-ΔN (residues 45–271) and UBC13 (residues 3–150) were amplified from the cDNAs obtained from Open Biosystems. The gene encoding human MMS2 (residues 6–143) was PCR-amplified from a human cDNA library. The gene encoding yeast SUMO was PCR-amplified from a Saccharomyces cerevisiae cDNA library. The gene encoding SUMO was attached to the N terminus of the genes encoding OTUB1-ΔN, UBC13, and MMS2. The amplified genes were cloned into the pET26b expression vector with NdeI and XhoI sites to produce N-terminal His$_6$-tagged SUMO fusion proteins and confirmed by DNA sequencing. Escherichia coli strain Rosetta$^\text{TM}$ (DE3) cells (Invitrogen) were transformed with the expression vector and cultured in LB containing 50 mg/liter kanamycin at 37 °C. The expression was induced by the addition of 0.1 mM isopropyl-$\beta$-D-thiogalactopyranoside at $A_{600}$ of $\sim$0.5, and then the E. coli cells were incubated overnight at 15 °C. The cells were collected by centrifugation at 8000 $g$ for 15 min and disrupted by sonication in the sonication buffer (50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 20 mM imidazole, and 0.5% Triton X-100). The lysates were centrifuged at 30,000 $g$ for 60 min, and the supernatants were then loaded onto a nickel-nitrilotriacetic acid (Qiagen) column that had been pre-equilibrated with the sonication buffer. The column was washed with the sonication buffer and then with 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 20 mM imidazole. The His$_6$-tagged SUMO fusion proteins were eluted with 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 200 mM imidazole. The His$_6$-tagged SUMO was cleaved by Ulp1 protease, and the samples were dialyzed against 50 mM Tris-HCl buffer (pH 8.0) containing 1 mM DTT. The proteins were loaded onto a ResourceQ anion exchange column (GE Healthcare) pre-equilibrated with 50 mM Tris-HCl buffer (pH 8.0) containing 1 mM DTT and were eluted with a linear gradient of 0–1 mM NaCl. To prepare the OTUB1-ΔN-UBC13-MMS2 complex, a 1.5-fold molar excess of UBC13 was incubated at 4 °C overnight with OTUB1-ΔN and MMS2. OTUB1-ΔN-UBC13-MMS2 complex was loaded onto a HiLoad Superdex 75 size-exclusion column (GE Healthcare) pre-equilibrated with 10 mM Tris-HCl buffer (pH 7.2), 50 mM NaCl, and 5 mM $\beta$-mercaptoethanol to remove unbound monomers.

Crystallography—The purified OTUB1-ΔN-UBC13-MMS2 complex was concentrated to 10 g/liter by using an Amicon Ultra-15 10,000 molecular weight cutoff filter (Millipore). Initial crystallization screening was performed using the sitting drop vapor diffusion method at 20 °C, with a Mosquito$^\text{L}$ liquid-handling robot (TTP Lab Tech). We tested about 600 conditions using crystallization reagent kits supplied by Hampton Research and Qiagen, and initial hits were further optimized. The best crystals of the OTUB1-ΔN-UBC13-MMS2 complex were obtained at 20 °C with the sitting drop vapor diffusion method by mixing 0.5 $\mu$L of protein solution with an equal amount of precipitant solution containing 90 mM Tris-HCl buffer (pH 8.5), 19% PEG3350, and 10 mM EDTA sodium salt and equilibrating against 500 $\mu$L of reservoir solution contain-
**Crystal Structure of Human OTUB1-UBC13-MMS2 complex**

**TABLE 1**

| Data collection and refinement statistics | Human OTUB1-ΔN-UBC13-MMS2 |
|------------------------------------------|---------------------------|
| Space group                              | P2₁                        |
| Unit cell parameter                      | a = 102.1 Å, b = 137.3 Å, c = 257.1 Å, β = 90.03° |
| Resolution (Å)                           | 1.00000                    |
| Unique reflections                       | 50.0–3.15 (3.20–3.15)      |
| Total reflections                         | 121,981                    |
| Completeness (%)                         | 341,500                    |
| R̃(I)                                    | 96.9 (92.6)                |
| Rfree (%)                                | 16.1 (3.08)                |
| Rfree (sym)                              | 0.083 (0.322)              |

\[ R̃(I) = \frac{\sum|I_{calc} - I_{obs}|}{\sum I_{obs}} \]
\[ Rfree = \frac{\sum|F_{calc} - F_{obs}|}{\sum F_{calc}} \text{ for reflections of working set.} \]
\[ Rfree (sym) = \frac{\sum|F_{calc} - F_{obs}|}{\sum F_{calc}} \text{ for reflections of test set (5% of total unique reflections).} \]

Data collection and refinement statistics

For data collection, the crystals were transferred to a cryostabilizing solution (50 mM Tris-Cl (pH 8.5), 24% PEG3350, and 20% ethylene glycol) and flash-frozen in a 100 K nitrogen stream. The crystal structures of the human OTUB1, OTUB2, and UBC13 were purified by glutathione-Sepharose FF and ResourceQ anion exchange columns (GE Healthcare). Experiments were carried out on a Biacore T200 instrument (GE Healthcare) equilibrated at 25 °C in HBS-P buffer including 10 mM HEPE (pH 7.4), 0.05% surfactant P-20 using a Sensor Chip CM5 (GE Healthcare). GST antibody (GE Healthcare) was covalently immobilized on the sensor chip at a density of about 15,000 resonance units (RUs), and GST-fused OTUB1, OTUB2 and UBC13 were captured on the sensor chip at a density of 500–1000 RUs. OTUB1, UBC13, and UBC13-MMS2 were then injected for 60 s at a flow rate of 10 ml/min. Dissociation constants (Kd) were calculated by fitting to a 1:1 interaction model using Biacore T200 evaluation software (GE Healthcare).

**Cell Culture and Plasmid Transfection**—U2OS cells and 293T cells were grown in McCoy’s 5A medium and Dulbecco’s modified Eagle’s medium with 10% FBS, respectively. Plasmid transfections were performed using Effectene (Qiagen) following the manufacturer’s protocol with minor modifications. pcDNA3-FLAG OTUB1, pcDNA3-HA RNF168, and pCMV-MYC ubiquitin expression vectors were described previously (21). Point mutations and deletions were generated by using PCR.

**Antibodies**—We used the following antibodies: 53BP1 (NB100-304, Novus Biologicals), histone H3 (ab1791, Abcam), Ub (Clone VU-1, VU101, LifeSensors), UBC13 (#4919, Cell Signaling), α-tubulin (T6074, Sigma), FLAG (M2, F3165, Sigma), HA (clone HA-7, H9658, Sigma), MYC (clone 9E10, sc-40, Santa Cruz).

**Western Blotting**—Cells were lysed in SDS sample buffer. Whole cell lysate were separated on SDS-PAGE (5–20% or 15% e-PAGEL, ATTO) and then transferred to nitrocellulose membranes by iBlot Gel Transfer System (Invitrogen). For Ub immunodetection, nitrocellulose membranes were incubated with 0.5% glutaraldehyde in PBS before blocking. Membranes were blocked with 5% Difco skim milk (BD Biosciences) in TBST and stained with the indicated primary antibodies followed by horseradish peroxidase (HRP)-conjugated secondary antibodies. Western Lightning ECL Pro (PerkinElmer Life Sciences) was used for chemiluminescent horseradish peroxidase-conjugated antibody detection. Chemiluminescent signals were detected with LAS4000 (Fuji Film).
In Vitro Ubiquitination Assay—Assays were set up in a total volume of 20 μl in 50 mM HEPES-KOH (pH 7.5), 100 mM NaCl, 5 mM MgCl₂, 2 mM ATP, 0.5 mM DTT. UBE1 (0.025 μM; Boston Biochem), 0.1 μM E2 (UBC13 and MMS2 or UBC13/UEV1a (Boston Biochem)), and Lys-63-only ubiquitin (20 μM Ub (Boston Biochem)) were incubated with 10 μM of recombinant OTUB1 proteins. The indicated proteins were assembled on ice for 30 min, and then the reaction was initiated by the addition of E1 and ATP. Reaction mixtures were incubated at 37 °C for 1, 2, 4, 6, 10, or 30 min or 2 h (UBC13/UEV1a) or 16 h (UBC13/MMS2).

Immunoprecipitation and Acid Extraction of Histones—10-cm dishes of 293T cells were grown, and each dish was transfected with 0.5 μg of pcDNA3-OTUB1, 4 μg of pcDNA3-HA RNF168, and 1 μg of pCMV-MYC ubiquitin expression vectors using Effectene (Qiagen). After 24 h of post-transfection, cells were harvested and divided in two. One sample was lysed in ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% digitonin supplemented with EDTA-free protease, and phosphatase inhibitor cocktails (Nacalai Tesque)). Cell lysates were sonicated and then clarified by centrifugation at 4 °C for 30 min at 15,000 × g. The nuclear pellet was extracted into 0.4N H₂SO₄ for 1 h at 4 °C. The acid soluble fraction was collected after centrifugation (5 min, 7500 × g), and the supernatant to a final concentration of 20% and then incubated on no. 1 glass coverslips (Fisher), and 0.1 μM of recombinant OTUB1 proteins. Reaction mixtures were incubated at 37 °C for 150 min.

RESULTS

Structure Determination of Human OTUB1-UBC13-MMS2 Ternary Complex—To reveal a mechanism of the interaction between human OTUB1 and UBC13 for the DUB activity-independent, non-canonical inhibition of ubiquitination, we tried crystallization of the full-length or N-terminal-truncated human OTUB1 (i.e. residues 45–271; referred to hereafter as OTUB1-ΔN) in complex with human UBC13 or UBC13(C87S/K92R)–Ub in the presence or absence of human MMS2 or UEV1a. C87S/K92R double mutation was introduced to UBC13 for preparing a stable oxyester-linked analog of the UBC13–Ub intermediate without producing a ubiquitinated UBC13 via Lys-92. Most of the crystallization trials failed, but a trial using the N-terminal truncated OTUB1, UBC13, and MMS2 was successful. The crystal comprising the ternary complex belongs to the space group P2₁, with unit cell dimensions of a = 102.1 Å, b = 137.3 Å, c = 257.1 Å, β = 90.03°. An asymmetric unit contains 18 complexes of UBC13-MMS2 and 6 molecules of OTUB1-ΔN. Three complexes of UBC13-MMS2 embrace one molecule of OTUB1-ΔN and constitute a structural unit OTUB1-ΔN-(UBC13-MMS2)₃ (supplemental S1). Furthermore, three OTUB1-ΔN-(UBC13-MMS2)₃ units are aligned in parallel and assembled into a cluster [OTUB1-ΔN-(UBC13-MMS2)₃]₉. The asymmetric unit contains two [OTUB1-ΔN-(UBC13-MMS2)₃]₉ clusters that are related with each other by a pseudo 2₃-fold symmetry along x and z axes of the unit cell. Therefore, the crystal of the ternary complex appears to belong to the space group P2₁2₁2₁.

In this packed complex of OTUB1-ΔN and the UBC13-MMS2 complex in the crystal, OTUB1-ΔN contacts four distinct UBC13-MMS2 complexes (Fig. 1a). For convenience, the UBC13-MMS2 complexes contacting a₀, b₀a₀9, a₅a₇a₀9 and the loop connecting a₀8 and a₀9 of OTUB1-ΔN are referred to as Complexes A, B, C, and D, respectively (Fig. 1a). To identify a biologically functional OTUB1-UBC13-MMS2 ternary complex, we first calculated a buried surface area at the interface between OTUB1-ΔN and UBC13 in Complex A, B, C, or D. The combination of OTUB1-ΔN and Complex C (721 Å²) buries a sufficiently larger contact surface than other combinations (114, 129, and 202 Å² for Complex A, B, and D, respectively). Furthermore, the contact of Complex C with OTUB1-ΔN is mediated exclusively by UBC13, consistent with the fact that neither MMS2 nor UEV1a is involved in the interaction between OTUB1 and UBC13 (Fig. 1a and b). These structural features suggest that the interactions between OTUB1-ΔN and UBC13 in Complex C should be physiologically functional (Fig. 1 and supplemental S1).
Interactions between OTUB1 and UBC13—Interactions between OTUB1-ΔN and UBC13 in Complex C are mainly hydrophobic. The side chains of Phe-138, Val-173, Leu-177, and Met-211 in OTUB1 form a hydrophobic surface that interacts with the side chains of Pro-63, Met-64, Pro-97, and Ala-98 in UBC13 (Fig. 1c and supplemental S2). Furthermore, the side chain of Phe-133 in OTUB1 is accommodated in a pocket formed by the aliphatic portions of the Lys-10, Glu-11, and Arg-14 side chains in UBC13. In addition, the N\textsubscript{ε} atom of Lys-213 in OTUB1 hydrogen bonds with the O\textsubscript{δ} atom and main-chain CO of Asp-93 in UBC13. The O\textepsilon atom of Glu-209 in OTUB1 hydrogen bonds with the O\textgamma atom of Ser-96 in UBC13. The Ser-96–Pro-97–Ala98 tripeptide sequence is conserved among OTUB1 binding E2s (i.e. UBC13 and UBE2D and UBE2E families) (28, 29) but not among other E2s (supplemental S3), suggesting that UBC13, UBE2D, and UBE2E families share a common strategy for OTUB1 binding.

To test whether these interactions actually contribute to the specific binding between OTUB1 and UBC13 in solution, we replaced Phe-133, Phe-138, Met-211, and Lys-213 by Ala in the full-length OTUB1 and measured the affinities by using surface plasmon resonance spectrometry (supplemental S4 and Table 2). As expected, these mutations reduced the affinities 33–50-fold, clearly indicating that the abovementioned interactions between OTUB1 and UBC13 occur in solution and contribute to the binding between them. Met-211 is conserved in both OTUB1 and OTUB2, and Phe-138 is perfectly conserved in OTUB1 and mostly in OTUB2 (supplemental S5). On the other hand, Phe-133 is conserved in OTUB1 but is replaced by His in OTUB2, and Lys-213 is conserved in OTUB1 but not in OTUB2. Therefore, Phe-133 and Lys-213 of OTUB1 may contribute to the specific binding between OTUB1 and UBC13.

Our surface plasmon resonance analyses show that OTUB1 binds UBC13 with a 40-fold higher affinity than OTUB2.

Structure-based Mutational Analysis of the Inhibition of Lys-63 Chain Synthesis by OTUB1 in Vitro—We next asked if these atomic-level interactions for the binding between OTUB1 and UBC13 are critical for the inhibition of Lys-63 chain synthesis in vitro. Lys-63 chain formation was reconstituted with E1, Lys-63-only Ub (i.e. K6R/K11R/K27R/K29R/K33R/K48R), and UBC13/MM2 or UBC13/UEV1a in the presence or absence of the wild type or mutant OTUB1, and then products were analyzed by Western blotting for Ub. In this experiment, DUB-inactive mutation C91S was additionally introduced to OTUB1 to avoid a nonspecific DUB activity affecting the result. In the presence of C91S mutant of OTUB1, UBC13/UEV1a- or UBC13/MM2-dependent Lys-63 chain formation was inhibited (Fig. 2,a and b, and supplemental S6, compare lanes 2 and 3). In striking contrast, C91S/F133A, C91S/F138A, and C91S/F133A/F138A/M211A mutants of OTUB1 showed no inhibitory effect (Fig. 2,a and b, and supplemental S6, lanes 4–6), whereas C91S/M211A mutant had a marginal inhibitory effect (Fig. 2,a and b, and supplemental S6, lane 7). Note that proper folding of F133A, F138A, M211A, and F133A/F138A/M211A mutants of OTUB1 was confirmed by their retaining full DUB activities (Fig. 3). These results indicate that the observed atomic-level interactions between OTUB1 and UBC13 are critical for the inhibition.

Structure-based Mutational Analysis of the Inhibition of DNA Damage Response by OTUB1 in Vivo—All the above data prompted us to confirm the significance of the OTUB1-UBC13 interaction through Phe-133, Phe-138, and Met-211 of OTUB1 at the cellular level. Binding between UBC13 and the wild type or mutant OTUB1 in cells was assessed by a co-immunoprecipitation experiment. As shown in Fig. 4a, the wild type FLAG-OTUB1 can be efficiently co-precipitated with UBC13. In contrast, F133A, F138A, and F133A/F138A/M211A mutants of FLAG-OTUB1 cannot be co-precipitated with UBC13, whereas M211A mutant can be fairly weakly co-precipitated. These results are consistent with the abovementioned Lys-63 ubiquitination inhibition analyses. We next analyzed the impact of F133A, F138A, and M211A mutations of OTUB1 on

### Table 2

|              | GST-OTUB1 | GST-OTUB2 | GST-UBC13 |
|--------------|-----------|-----------|-----------|
|              | UBC13     | UBC13-MMS2| OTUB1     |
| WT           | 8.98 ± 1.75| 17.5 ± 6.2| 19.2 ± 1.8| 23.2 ± 1.1|
| C91S         | 2.85 ± 0.14| 5.68 ± 0.41|           |
| F133A        | 372 ± 4   |           |           |
| F138A        | 296 ± 6   |           |           |
| M211A        | 445 ± 40  |           |           |
| M211A/F133A/F138A | ND        |           |           |
| K213A        | 449 ± 21  |           |           |

These results are consistent with the abovementioned Lys-63 ubiquitination inhibition analyses. We next analyzed the impact of F133A, F138A, and M211A mutations of OTUB1 on...
RNF168-dependent histone ubiquitination, which can be detected from acid-extracted histone from 293T cells transfected with plasmids expressing HA-RNF168 and MYC-Ub (Fig. 4a, lane 2, lower panels). When these plasmids were co-transfected with FLAG-OTUB1-expressing plasmids, histone ubiquitination was completely suppressed (Fig. 4a, lane 3, lower panels). In contrast, F133A, F138A, and F133A/F138A/M211A mutants of OTUB1 showed no inhibitory effect (Fig. 4a, lanes 4–6, lower panels). M211A, which weakly binds UBC13, mildly inhibited histone ubiquitination (Fig. 4a, lane 7, lower panels).

RNF168/UBC13-dependent histone ubiquitination is prerequisite for localization of 53BP1 to sites of DSBs, which is visualized as irradiation induced foci by immunofluorescence (11, 13). Overexpression of OTUB1 inhibits Lys-63 chain and 53BP1 irradiation induced foci (21). Therefore, we finally tested whether F133A, F138A, and/or M211A mutations abrogated the OTUB1-dependent suppressive regulation of DNA damage response. U2OS cells overexpressing OTUB1 showed defective 53BP1 irradiation induced foci, whereas overexpression of any OTUB1 mutants did not inhibit 53BP1 irradiation induced foci efficiently. Especially, F133A/F138A/M211A mutant of OTUB1 completely lost its inhibitory effect on DNA damage response (Fig. 4, b and c).

Altogether, we concluded that OTUB1 inhibits E2 activity of UBC13 and the downstream UBC13/RNF168-mediated DNA damage response depending on the affinity between OTUB1 and UBC13 through specific interactions observed in the present OTUB1-UBC13-MMS2 ternary complex structure.

**Otub1 Delays Di-Ub Production and Completely Blocks Tri-Ub Production in Vitro**

Our in vitro ubiquitination inhibition assay shows that Lys-63-linked di-Ub formation is inhibited in the presence of OTUB1 in a short time scale (i.e., ∼30 min) (Fig. 2b). Furthermore, more detailed time course analysis with time points of 1, 2, 4, 6, and 10 min clearly demonstrates that di-Ub formation is sufficiently delayed in the presence of OTUB1 (Fig. 5). Recently, the crystal structures of the Ub-UBCH5b-OTUB1-Ub and Ub−UBC13-OTUB1−Ub complexes have been reported (22, 23).
**Crystal Structure of Human OTUB1-UBC13-MMS2 complex**

**FIGURE 4. Phe-133, Phe-138, and Met-211 of OTUB1 are required for the inhibition of UBC13/RNF168-mediated DNA damage response.** a, 293T cells cotransfected with hemagglutinin (HA)-RNF168, MYC-ubiquitin, and/or FLAG-OTUB1 were subjected to FLAG immunoprecipitation (IP) or acid extraction of chromatin. WCL, whole cell lysate. b and c. U2OS cells transfected with the indicated FLAG-OTUB1 expression vectors were irradiated with 2 gray (Gy) and processed for 53BP1 and FLAG immunofluorescence 1 h post-ionizing radiation. Scale bar, 25 μm. c. shown is quantification of the data shown in b (mean ± S.D., n = 3). Gy, gray; WCL, whole cell lysate; IP, immunoprecipitation.

**FIGURE 5. OTUB1 mildly inhibits UBC13-dependent di-Ub formation.** In vitro Lys-63 chain synthesis by UBC13-UEV1a was performed in the presence of C91S or F133A/F138A/M211A/C91S OTUB1. Reaction products were analyzed by Western blotting for Ub after incubation for the indicated time at 37 °C.

OTUB1 (i.e. residues 22–46), which is required for the E2 inhibition, folds into an α-helix and interacts with Ile-44-centered patch of the donor Ub charged to UBC13b and UBC13. For the inhibition of UBC13b (and possibly, other OTUB1-interacting E2s), the edge of the helix partly shields a thioester linkage between the active site Cys of E2 and the terminal Gly of the donor Ub, thus likely interfering with a transesterification reaction to form an isopeptide linkage between the donor and acceptor Ub molecules. For UBC13 inhibition, it is likely that the N-terminal helix of OTUB1 sterically interferes with the binding between UBC13 and UEV1a/MMS2, which provides a binding site for the acceptor Ub and thus is required for Lys-63 chain formation. Interfering with the transesterification reaction and/or UEV1a/MMS2 binding by OTUB1 can explain how OTUB1 delays Lys-63-linked di-Ub production.

On the other hand, in the detailed time course analysis, we found that the amount of di-Ub gradually increased, whereas no tri-Ub could be detected. Even in a longer time scale (i.e., ~2 h), tri-Ub formation is completely blocked in the presence of OTUB1 despite di-Ub being sufficiently produced (Fig. 2b). These results indicate that OTUB1 suppresses Lys-63-linked tri-Ub formation more strongly than Lys-63-linked di-Ub formation, which postulates another additional mechanism for the inhibition of Lys-63 chain synthesis for the complete blocking of tri-Ub production, as discussed below.

**DISCUSSION**

A molecular mechanism of Lys-63 chain synthesis by the UBC13-MMS2/UEV1a complex has been proposed on the basis of the crystal structure of yeast UBC13–Ub-MMS2 binary complex. The UBC13-MMS2 complex forms two adjacent Ub binding sites termed “acceptor site” and “donor site.” The donor Ub charged to the active site Cys by a thioester bond binds to the donor site, and then the acceptor Ub is recruited to the acceptor site. This places Lys-63 of the acceptor Ub in the active site, near the thioester bond between the donor Ub and UBC13. The Nα atom of Lys-63 of the acceptor Ub can then attack the thioester and form an isopeptide bond between the terminal carboxyl group of the donor Ub and Lys-63 of the acceptor Ub. After that, the donor Ub becomes the acceptor Ub for the next round of Lys-63-linked isopeptide formation, although it is not clear whether the donor Ub moves to the acceptor site on the same UBC13-MMS2/UEV1a complex or binds to the acceptor site on another complex. In either case, binding of the distal Ub moiety in the nascent di-Ub to the acceptor site of the UBC13-MMS2/UEV1a complex for tri-Ub chain formation should be a step to be potentially inhibited by OTUB1.

A docking model of the OTUB1-UBC13–Ub(donor)-MMS2-Ub(acceptor) quaternary complex, which was built by superposing the present OTUB1-ΔN-UBC13-MMS2 complex on the reported UBC13–Ub-MMS2 and Ub–UBCH5b-OTUB1-Ub complexes (Ca root mean square deviation values of 2.65 and 2.60 Å over 280 and 362 residues, respectively) enabled us to propose the following models for the inhibition of Lys-63 chain synthesis by OTUB1 (Fig. 6). The OTUB1-UBC13-MMS2 ternary complex remains on the nascent di-Ub in the elongation cycle of Lys-63 chain synthesis, likely due to the enhanced affinity through the interaction with the charged Ub and behaves as a capping protein for the nascent di-Ub. This capping can sterically block the binding of the acceptor Ub at the distal terminus to the acceptor site of a new UBC13–Ub-MMS2 complex. Additionally, the modeled N-terminal helix of
OTUB1 intervenes between the distal and proximal Ub moieties of the nascent di-Ub so as to prevent the translocation of the di-Ub chain on the same UBC13-MMS2/UEV1a complex, thus further blocking the next Ub transfer from E1 to UBC13, for the next round of the isopeptide formation. These capping and translocation inhibition models postulate that the concentration of OTUB1 should be comparable to that of the Ub-charged UBC13, which has been shown by Durocher and co-workers (23). OTUB1 is more abundant than UBC13 in U2OS and 293T cells.

In OTUB1-overexpressing cells, monoubiquitination of histones during DNA damage response could be detected, but diubiquitination could not, possibly due to an intrinsic high DUB activity in cells. On the other hand, OTUB1-E2 complex structures illustrate that OTUB1 binding surfaces of E2s overlap with E3 RING binding surfaces, implying multivalent inhibition strategies for regulating DNA damage responses. Further discussion awaits future studies on E2-E3 relationships and roles of specific types and/or lengths of Ub chains during DNA damage responses, which still remain controversial.

REFERENCES

1. Glickman, M. H., and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway. Destruction for the sake of construction. Physiol. Rev. 82, 373–428
2. Grabbe, C., Husnjak, K., and Dikic, I. (2011) The spatial and temporal organization of ubiquitin networks. Nat. Rev. Mol. Cell Biol. 12, 295–307
3. Hofmann, R. M., and Pickart, C. M. (1999) Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96, 645–653
4. VanDemark, A. P., Hofmann, R. M., Tsui, C., Pickart, C. M., and Wolberger, C. (2001) Molecular insights into polyubiquitin chain assembly. Crystal structure of the Mms2/Ubc13 heterodimer. Cell 105, 711–720
5. Eddins, M. J., Carlile, C. M., Gomez, K. M., Pickart, C. M., and Wolberger, C. (2006) Mms2-Ubc13 covalently bound to ubiquitin reveals the structural basis of linkage-specific polyubiquitin chain formation. Nat. Struct. Mol. Biol. 13, 915–920
6. Kim, H., Chen, J., and Yu, X. (2007) Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316, 1202–1205
7. Solshian, B., Shao, G., Lilli, D. R., Culhane, A. C., Moreau, L. A., Xia, B., Livingston, D. M., and Greenberg, R. A. (2007) RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316, 1198–1202
8. Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., and Elledge, S. J. (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316, 1194–1198
9. Kinner, A., Wu, W., Staudt, C., and Iliakis, G. (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678–5694
10. Yan, J., and Jetten, A. M. (2008) RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett. 271, 179–190
11. Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D. H., Pepperkok, R., Ellenberg, J., Panier, S., Durocher, D., Bartek, J., Lukas, J., and Lukas, C. (2009) RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435–446
12. Panier, S., and Durocher, D. (2009) Regulatory ubiquitylation in response to DNA double-strand breaks. DNA Repair 8, 436–443
13. Stewart, G. S., Panier, S., Townsend, K., Al-Hakim, A. K., Kolas, N. K., Miller, E. S., Nakada, S., Ylanko, J., Olivierius, S., Mendez, M., Oldreive, C., Wildenhain, J., Tagliaferro, A., Pelletier, L., Taubenheim, N., Durandy, A., Byrd, P. J., Stankovic, T., Taylor, A. M., and Durocher, D. (2009) The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 136, 420–434
14. Sims, I. J., and Cohen, R. E. (2009) Linkage-specific avidity defines the lysine 63-linked polyubiquitin binding preference of rap80. Mol. Cell 33, 775–783
15. Sato, Y., Yoshikawa, A., Mimura, H., Yamashita, M., Yamagata, A., and Fukai, S. (2009) Structural basis for specific recognition of Lys-63-linked polyubiquitin chains by tandem UIMs of RAP80. EMBO J. 28, 2461–2468
16. Huen, M. S., Grant, R., Manke, I., Minn, K., Yu, X., Yaffe, M. B., and Chen, J. (2007) RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131, 901–914
17. Mailand, N., Bekker-Jensen, S., Faustrop, H., Melander, F., Bartek, J., Lukas, C., and Lukas, J. (2007) RNF8 ubiquitates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887–900
18. Kolas, N. K., Chapman, J. R., Nakada, S., Ylanko, J., Chahwan, R., Sweeney, F. D., Panier, S., Mendez, M., Wildenhain, J., Thomson, T. M., Pelletier, L., Jackson, S. P., and Elledge, S. J. (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316, 1194–1198
19. Stewart, G. S., Panier, S., Townsend, K., Al-Hakim, A. K., Kolas, N. K., Miller, E. S., Nakada, S., Ylanko, J., Olivierius, S., Mendez, M., Oldreive, C., Wildenhain, J., Tagliaferro, A., Pelletier, L., Taubenheim, N., Durandy, A., Byrd, P. J., Stankovic, T., Taylor, A. M., and Durocher, D. (2009) The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 136, 420–434
20. Sims, I. J., and Cohen, R. E. (2009) Linkage-specific avidity defines the lysine 63-linked polyubiquitin binding preference of rap80. Mol. Cell 33, 775–783
Crystal Structure of Human OTUB1-UBC13-MMS2 complex

21. Nakada, S., Tsi, I., Panier, S., Al-Hakim, A., Iemura, S., Juang, Y. C., O’Donnell, L., Kumakubo, A., Munro, M., Sicheri, F., Gingras, A. C., Natsume, T., Suda, T., and Durocher, D. (2010) Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. *Nature* **466**, 941–946

22. Wiener, R., Zhang, X., Wang, T., and Wolberger, C. (2012) The mechanism of OTUB1-mediated inhibition of ubiquitination. *Nature* **483**, 618–622

23. Juang, Y. C., Landry, M. C., Sanches, M., Vittal, V., Leung, C. C., Ceccarelli, D. F., Mateo, A. R., Pruneda, J. N., Mao, D. Y., Szilard, R. K., Orlicky, S., Munro, M., Brzovic, P. S., Klevit, R. E., Sicheri, F., and Durocher, D. (2012) OTUB1 co-opts Lys-48-linked ubiquitin recognition to suppress E2 enzyme function. *Mol. Cell* **45**, 384–397

24. Otwinowski, Z., and Minor, W. (1997) *Methods Enzymol.* **276**, 307–326

25. Collaborative Computational Project, Number 4 (1994) The CCP4 suite. Programs for protein crystallography. *Acta Crystallogr. D Biol. Crystallogr* **50**, 760–763

26. Vagin, A., and Teplyakov, A. (1997) *J. Appl. Crystallogr.* **30**, 1022–1025

27. Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. *Acta Crystallogr D Biol. Crystallogr* **60**, 2126–2132

28. Natsume, T., Yamauchi, Y., Nakayama, H., Shinkawa, T., Yanagida, M., Takahashi, N., and Isobe, T. (2002) A direct nanoflow liquid chromatography-tandem mass spectrometry system for interaction proteomics. *Anal. Chem.* **74**, 4725–4733

29. Goudreault, M., D’Ambrosio, L. M., Kean, M. J., Mullin, M. J., Larsen, B. G., Sanchez, A., Chaudhry, S., Chen, G. I., Sicheri, F., Nesvizhskii, A. I., Aebersold, R., Raught, B., and Gingras, A. C. (2009) A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. *Mol. Cell. Proteomics* **8**, 157–171